Fiche publication
Date publication
janvier 2016
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HAFFEN Emmanuel
Tous les auteurs :
Fond G, Bennabi D, Haffen E, Brunel L, Micoulaud-Franchi JA, Loundou A, Lançon C, Llorca PM, Auquier P, Boyer L
Lien Pubmed
Résumé
The aim of this study was to assess the efficacy and tolerability/acceptability of 6 anesthetic agents in ECT for depressive disorders. We systematically reviewed 14 double-blind randomized controlled trials (610 participants). Efficacy was measured by the mean scores on validated depression scales at 6 ECT (or the nearest score if not available), number of responders at the end of treatment and seizure duration. The acceptability was measured by the proportion of patients who dropped out of the allocated treatment, and the tolerability by the number of serious adverse events and post-treatment cognition assessment. After excluding the trials responsible for heterogeneity, depression scores of patients who were administered methohexital were found to be significantly more improved than those who received propofol (p = 0.001). On the contrary, those who were administered propofol had lower depression scores than those with thiopental at the end of treatment (p = 0.002). Compared to propofol, methohexital was found to be significantly associated with higher seizure duration (p = 0.018). No difference was found for the acceptability profile (all p > 0.05). In summary, ketamine and methohexital may be preferred to propofol or thiopental in regard of effectiveness in depression scores and increased seizure duration. Further studies are warranted to compare ketamine and methohexital.
Mots clés
Anesthetics, adverse effects, Bayes Theorem, Depressive Disorder, Major, drug therapy, Electroconvulsive Therapy, Electroencephalography, Humans, Ketamine, adverse effects, Methohexital, adverse effects, Randomized Controlled Trials as Topic, Seizures, drug therapy
Référence
Sci Rep. 2016 Jan 25;6:19847
